Ciclesonide for the treatment of asthma

Therapeutics and Clinical Risk Management

Volumn 2, Issue 1, 2006, Pages 25-37

  Dahl, Ronald ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adults; Asthma; Children; Ciclesonide; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO; SALBUTAMOL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; HEADACHE; HOARSENESS; HUMAN; INCIDENCE; METERED DOSE INHALER; NONHUMAN; PHARMACODYNAMICS; PHARYNGITIS; QUALITY OF LIFE; REVIEW; RHINITIS; SCORING SYSTEM; SPIROMETRY; SYMPTOM; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

EID: 33745475106     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Agertoft L, Pedersen S. 2005. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol, 115:940-5.
2. Belvisi MG, Bundschuh D, Stoeck M, et al. 2005. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther, 314:568-74.
3. Berger W, Galant S, Kundu S, et al. 2005. Long term safety profile of once-daily ciclesonide in adults/adolescents with mild-to-moderate persistent asthma [abstract]. 61st Annual Meeting of the American Academy of Allergy, Asthma and Immunology. March 18-22 2005. San Antonio, TX, USA. 33.
4. Berger WE, Mansfield L, Pinter C, et al. 2004. Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once-daily doses of 80μg, 160μg, and 320μg in the treatment of patients with mild-to-moderate asthma. J Allergy Clin Immunol, 113(Suppl):50A.
5. Bernstein D, Nathan R, Ledford D, et al. 2005. Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma [abstract]. J Allergy Clin Immunol, 115(Suppl):210:836.
6. Bernstein JA, Noonan MJ, Rim C, et al. 2004. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma [abstract]. J Allergy Clin Immunol, 113(Suppl):349.
7. Bethke TD, Nave R, Zech K, et al. 2003. Pharmacokinetics of ciclesonide and its active principle in asthma patients and healthy subjects after single-dose inhalation [abstract]. J Allergy Clin Immunol, 111(Suppl. 2):217:593.
8. Boulet LP, Engelstatter R, Magyar P, et al. 2003. Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma. Am J Respir Crit Care Med, 167:A771.
9. British Thoracic Society, Scottish Intercollegiate Guidelines Network. 2004. British guideline on the management of asthma: A national clinical guideline [online]. Accessed 12 December 2005. URL: http:// www.brit-thoracic.org.uk/.
10. Buhl R, Vmkler I, Magyar P, et al. 2004. Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma [abstract]. Eur Resp J, 24(Suppl):346S:2177.
11. Busse W, Kaliner M, Bernstein D, et al. 2005. The novel inhaled corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma [abstract]. J Allergy Clin Immunol, 115(Suppl):213:846.
12. Campbell LM. 1999. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs, 58(Suppl 4): 25-33.
13. Chapman KR, Patel P, Boulet LP, et al. 2002. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur Respir J, 20(Suppl 38):373-4.
14. Chapman KR, Patel P, D'Urzo AD, et al. 2005. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy, 60:330-7.
15. Derom E, Van De Velde V, Marissens S, et al. 2005. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulm Pharmacol Ther, 18:328-36.
16. Ellepola AN, Samaranayake LP. 2001. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis, 7:211-16.
17. Engelstatter R, Banerji D, Stenijans VW. 2004. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis. Am J Respir Crit Care Med, 169:A92.
18. Gadgil DA, Niphadkar P, Jagannath KT, et al. 2005. Once-daily ciclesonide is as effective as twice-daily budesonide in maintaining lung function and asthma control in patients with asthma [abstract]. J Allergy Clin Immunol, 115(Suppl):3:11.
19. Gauvreau GM, Watson RM, Postma DS, et al. 2005. Effect of ciclesonide 40 μg and 80 μg on early and late asthmatic reaction, and sputum eosinophils after allergen challenge in patients with mild asthma [abstract]. J Allergy Clin Immunol, 115:834.
20. Gelfand E, Boguniewicz M, Weinstein S, et al. 2005. Ciclesonide, administered once daily, has a low incidence of oropharyngeal adverse events in pediatric asthma patients [abstract]. J Allergy Clin Immunol, 115:847.
21. [GIA] Global Initiative for Asthma. 2004. Pocket guide for asthma management and prevention [online]. Accessed 12 December 2005/ URL: http://www.ginasthma.com.
22. [GIA] Global Initiative for Asthma. 2005. Global burden of asthma [online]. Accessed 18 April 2005/ URL: http://www.ginasthma.com.
23. Gu Z, Howell S, Liu D, et al. 2004. In vitro metabolism of 14C-ciclesonide in hepatocytes from mice, rats, rabbits, dogs and humans [abstract]. AAPS Journal, 6:W5295.
24. Hafner D, Kassel G, Wurst W, et al. 2004. The incidence of adverse events is comparable in asthma patients receiving ciclesonide or placebo: results from a pooled analysis [abstract]. Thorax, 59:ii71:P94.
25. Hansel T, Biberger C, Engelstatter R. 2004. Ciclesonide 80 μg or 320 μg once daily achieves lung function improvement comparable with budesonide 200 μg twice daily in patients with persistent asthma [abstract]. Thorax, 59(Suppl 2):ii71:P93.
26. Hasselgren M, Arne M, Lindahl A, et al. 2001. Estimated prevalences of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand J Prim Health Care, 19:54-7.
27. Hubbard R, Tattersfield A. 2004. Inhaled corticosteroids, bone mineral density and fracture in older people. Drugs Aging, 21:631-8.
28. Kanniess F, Richter K, Bohme S, et al. 2001. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther, 14:141-7.
29. Kerwin E, Chervinsky P, Fish J. 2004. Ciclesonide has no effect on hypothalamic-pituitary-adrenal (HPA)-axis at once-daily doses of 80 μg, 160 μg or 320 μg in the treatment of patients with mild-to-moderate asthma. Am J Respir Crit Care Med, 169:A90.
30. Langdon CG, Adler M, Mehra S, et al. 2005. Once-daily ciclesonide 80 or 320 mg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med, 99:1275-85.
31. Larsen BB, Nielsen LP, Engelstatter R, et al. 2003. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy, 58:207-12.
32. Lee DK, Fardon TC, Bates CE, et al. 2005. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest, 127:851-60.
33. Lee DK, Haggart K, Currie GP, et al. 2004. Effects of hydrofluoroalkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol, 58:26-33.
34. Leung SY, Eynott P, Nath P, et al. 2005. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J Allergy Clin Immunol, 115:989-96.
35. Lipworth BJ, Kaliner MA, LaForce CF, et al. 2005. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol, 94:465-72.
36. Magnussen H, Hofman J, Novakova B, et al. 2005. Ciclesonide 80 μg or 160 μg once-daily is as effective as fluticasone propionate 88 μg twice-daily in the treatment of persistent asthma [abstract]. J Allergy Clin Immunol, 115(Suppl):4:12.
37. Martin LE, Harrison C, Tanner RJ. 1975. Metabolism of beclomethasone dipropionate by animals and man. Postgrad Med J, 51(Suppl 4): 11-20.
38. Miller D, Ratner P, Condemi J, et al. 2005. Once-daily ciclesonide improves quality of life in pediatric patients with asthma [abstract]. J Allergy Clin Immunol, 115:838.
39. Mollmann H, Derendorf H, Barth J, et al. 1997. Pharmacokinetic/ pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol, 37:893-903.
40. National Asthma Education and Prevention Program. 2002. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol, 110:S141-S219.
41. Nave R, Bethke TD, van Marle SP, et al. 2004a. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet, 43:479-86.
42. Nave R, Fisher R, Zech K. 2003. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Poster presented at 99th International Conference of the American Thoracic Society. May 16-21 2003. Seattle, WA, USA.
43. Nave R, Meyer W, Fuhst R, et al. 2005a. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther, 18:390-6.
44. Nave R, Schmidt B, Hummel R. 2004b. Highly lipophilic fatty acid esters of the active metabolite of ciclesonide formed in vitro in rat lung tissue [abstract]. Eur Respir J, 48:345s:2170.
45. Nave R, Zech K, Bethke TD. 2005b. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol, 61:203-8.
46. Nayak A, Charous BL, Finn A, et al. 2005. A novel inhaled corticosteroid ciclesonide significantly improves quality of life in patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol, 115:837.
47. 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients [abstract]. Eur Respir J, 48:583s:3581.
48. O'Connor BJ, Sips P, Engelstatter R, et al. 2002. Management of moderate to severe bronchial asthma by ciclesonide: a 12 week trial. Am J Respir Crit Care Med, 165(8 Pt 2): A767.
49. O'Connor BJ, Kilfeather S, Cheung D, et al. 2002. Treatment of moderate to severe asthma with ciclesonide: a long term investigation over 52 weeks [abstract]. Eur Respir J, 20(Suppl. 38):406s:2579.
50. Pauwels RA, Pedersen S, Busse WW, et al. 2003. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet, 361:1071-6.
51. Pearlman D, Creticos P, Lampl K, et al. 2005. Once-daily ciclesonide is effective and well-tolerated in adult and adolescent patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol, 115:845.
52. Pedersen S, Garcia Garcia ML, Manjra AJ. 2004a. Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma [abstract]. Eur Respir J, 48:346s:2176.
53. Pedersen S, Gyurkovits K, von Delft KHE. 2004b. Safety profile of ciclesonide as compared with fluticasone propionate in the treatment of children and adolescents with asthma [abstract]. Eur Respir J, 48:346s:2175.
54. Pfister M, Krishnaswami S, Rohatagi S. 2004. Characterization of cortisol circadian rhythm and lack of cortisol suppression by a new corticosteroid, ciclesonide [abstract]. Proceedings of the 13th meeting of the Population Approach Group in Europe. June 17-18 2004. Uppsala, Sweden.
55. Postma DS, Sevette C, Martinat Y, et al. 2001. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J, 17:1083-8.
56. Richter K, Kanniess F, Biberger C, et al. 2005. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol, 45:146-52.
57. Rohatagi S, Appajosyula S, Derendorf H, et al. 2004. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol, 44:37-47.
58. Rohatagi S, Arya V, Zech K, et al. 2003a. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol, 43: 365-78.
59. Rohatagi S, Bye A, Falcoz C, et al. 1996. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol, 36:938-41.
60. Rohatagi S, Derandorf H, Zech K, et al. 2003b. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide [abstract]. J Allergy Clin Immunol, 111(2 Suppl.):S218:598.
61. Rohatagi S, Luo Y, Shen L, et al. 2005. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther, 12:201-9.
62. Ryrfeldt A, Andersson P, Edsbacker S, et al. 1982. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl, 122:86-95.
63. Salvatoni A, Piantanida E, Nosetti L, et al. 2003. Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. Paediatr Drugs, 5:351-61.
64. Serpero L, Petecchia L, Silvestri M. 2004. In vitro modulation of the cytokine-induced human bronchial epithelial cell (HBEC) functions by ciclesonide (CIC) [abstract]. Eur Respir J, 24(Suppl)48:346s:2173.
65. Shapiro G, Bensch G, R L, et al. 2005. Once-daily treatment with ciclesonide is effective and well tolerated in children with persistent asthma [abstract]. J Allergy Clin Immunol, 115:S6:20.
66. Spallarossa D, Battistini E, Silvestri M, et al. 2003. Steroid-naive adolescents with mild intermittent allergic asthma have airway hyperresponsiveness and elevated exhaled nitric oxide levels. J Asthma, 40:301-10.
67. Stoeck M, Riedel R, Hochhaus G, et al. 2004. In vitro and in vivo antiinflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther, 309:249-58.
68. Subbarao PJ, Duong M, Otis J, et al. 2005. Ciclesonide is effective in protecting against exercise-induced bronchoconstriction [abstract]. J Allergy Clin Immunol, 115:3.
69. Taylor DA, Jensen MW, Kanabar V, et al. 1999. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med, 160:237-43.
70. Ukena D, Biberger C, von Behren V, et al. 2003. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study [abstract]. Eur Respir J Suppl, 22(S45):P2640.
71. Weinbrenner A, Huneke D, Zschiesche M, et al. 2002. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab, 87:2160-3.
72. Williams LK, Pladevall M, Xi H, et al. 2004. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol, 114:1288-93.